2014 Interventions of Interest: Sulfonylureas Insulin Dipeptidyl peptidase-4 (DPP-4) inhibitors Glucagon-like peptide-1 (GLP-1) receptor agonists Continuous blood glucose monitoring The management of type 2 diabetes has received significant attention over the past decade due to the increasing prevalence of this condition and the rise in costs associated with its treatment. Approximately 29 million Americans have […]
Intervention of interest: Insulin degludec (Tresiba®, Novo Nordisk A/S). The Centers for Disease Control and Prevention (CDC) estimates that 29.1 million Americans have diabetes and 1.7 million adults are newly diagnosed with diabetes mellitus (DM) each year. To treat diabetes, approximately 6 million Americans use insulin therapy as part of their treatment plan to control […]
Interventions of Interest: Emicizumab-kxwh (Hemlibra®, Genentech) Hemophilia A is an inherited condition that results in a deficiency in the factor VIII blood clotting protein. Individuals with hemophilia A are at risk for life-threatening bleeding; bleeding into a joint or muscle is common and can lead to substantial disability. To reduce the risk of bleeding, patients […]
Interventions of interest, May 2015: Devices Temporary intragastric balloon systems (e.g., Silimed®, ReShape®) Vagus nerve block devices (e.g., Maestro® system) Duodenal-jejunal bypass liner (EndoBarrier®) Medications Naltrexone/bupropion sustained-release (Contrave®) Phentermine/topiramate extended-release (Qsymia®) Lorcaserin (Belviq®) Liraglutide (Saxenda®) Intervention of interest, April 2015: Roux-en-Y gastric bypass (RYGB) Biliopancreatic diversion/duodenal switch (BPD/DS) Laparoscopic adjustable gastric banding (LAGB) Vertical sleeve […]
Interventions of Interest: The Midwest CEPAC unanimously determined the evidence is adequate to demonstrate that CAR-T treatments ide-cel and cilta-cel both provide a net health benefit when compared to usual care; despite these benefits, for ide-cel, the only CAR-T agent having received FDA approval at this time, a majority of panelists voted that it represents […]
Interventions of Interest: Anti IL-23 agents: Guselkumab (Tremfya®, Janssen/Johnson & Johnson), tildrakizumab (Ilumya™, Sun Pharma), risankizumab (Skyrizi®, AbbVie) Anti TNF agent: Certolizumab pegol (Cimzia®, UCB) Plaque psoriasis is a common disease that causes red, scaly, raised lesions on the skin, most commonly on the elbows, knees, scalp, and back. Psoriasis affects about 2% of the […]
Interventions of interest: Anti TNF agents: Adalimumab (Humira®, AbbVie), etanercept (Enbrel®, Amgen, Inc.), infliximab (Remicade®, Janssen) Anti IL-17A agents: Secukinumab (Cosentyx®, Novartis), ixekizumab (Taltz®, Eli Lilly and Co.), brodalumab (SiliqTM, Valeant Pharmaceuticals and AstraZeneca) Anti IL-12/23 agent: Ustekinumab (Stelara®, Janssen) Anti PDE4 agent: Apremilast (Otezla®, Celgene) Plaque psoriasis is a common disease that causes red, scaly, raised lesions on […]
Interventions of Interest: roxadustat (AstraZeneca and FibroGen, Inc.) Anemia is common in patients with CKD and generally becomes more prevalent with decreasing hemoglobin (Hb) levels as CKD progresses from dialysis-independent CKD (DI-CKD) to dialysis-dependent CKD (DD-CKD). Risk factors for CKD include genetic or sociodemographic predisposition, or the presence of diseases that can initiate and worsen […]
Interventions of Interest: During the public meeting, an independent appraisal committee voted unanimously (15-0) that the evidence was not adequate to demonstrate that aducanumab plus supportive care provides a net health benefit when compared to supportive care alone. In light of substantial uncertainty of patient benefit, policy recommendations call for: Date of Review: July 2021 For questions, please […]
Interventions of Interest: lanadelumab (Takhzyro™,Shire) C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire) In 2018, ICER assessed the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. […]